Compass Therapeutics, Inc. ((CMPX)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Compass Therapeutics, Inc. (CMPX) recently completed a Phase 2 clinical study titled A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens. The study aimed to evaluate the efficacy of CTX-009, a potential treatment for patients with metastatic colorectal cancer who have undergone multiple chemotherapy regimens. This study is significant as it explores new treatment avenues for a patient group with limited options.
The intervention tested in this study is CTX-009, an experimental drug administered through intravenous infusion on day 1 and 15 of every 28-day cycle. The purpose of CTX-009 is to provide a new therapeutic option for patients with advanced colorectal cancer.
The study was designed as an open-label, adaptive Simon Two-Stage trial. Initially, 37 patients were enrolled, with the potential to expand to 84 if criteria were met. The study followed a single-group intervention model with no masking, focusing primarily on treatment efficacy.
The study began on December 8, 2022, and was completed with the last update submitted on June 24, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for investors to gauge the development pace.
With the study’s completion, Compass Therapeutics may see a positive impact on its stock performance as investor confidence could rise due to the potential success of CTX-009. This development places Compass in a competitive position within the oncology market, particularly in treatments for metastatic colorectal cancer.
The study is completed, and further details can be accessed on the ClinicalTrials portal.